Clinical Trial Update: A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II, single-arm trial evaluating the efficacy and safety of QL1706 in a targeted-immunotherapy-resistant hepatocellular carcinoma setting; currently active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• QL1706

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma (HCC), Second Line Treatment | Phase 2 | Status: ACTIVE_NOT_RECRUITING